Loading
Life sciences · Journal article
Frontiers in Oncology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Prion proteins (PrP) are primarily known for their role in neurodegenerative conditions like Creutzfeldt-Jakob Disease, where the misfolded, pathogenic isoform PrPSc propagates by using the normal cellular prion protein, PrP c, as a template, leading to aggregation and neuronal death. PrP c is a widely expressed glycoprotein that, beyond its role in prion disease, has emerged in specific contexts as a modulator of several hallmark cancer processes, including proliferation, apoptosis resistance, cellular signaling, adhesion, survival, and motility. This paper explores current evidence on how PrP c, and its misprocessed isoform pro-PrP, contribute to tumor progression across multiple cancer types, using colorectal cancer (CRC) as a unifying disease model to integrate mechanisms that are otherwise dispersed across the literature. This review will examine PrP c ’s role in sustaining proliferative signaling, resisting apoptosis, promoting migration and metastasis through its interaction with filamin A (FLNa), and contributing to therapy resistance. The goal is to consider the extent to which these mechanisms converge specifically in CRC, and what this means for PrP c ’s potential as a diagnostic and therapeutic target.